Our team has been investigating the role of immune checkpoints and cytokines during the effector and regulatory immune responses that lead to autoimmune diseases or induce immune tolerance. Currently, we are interested in applying this knowledge to understand the host responses driven by immunotherapeutic biologics and cell and gene remedies that cause harm to the patients (i.e., cytokine storm syndrome) and/or neutralize the therapeutic principles (i.e., anti-drug antibody responses). To this end, we will use state of the art immunology, genomics and nanomedicine technologies to bridge preclinical experimentation with functional evaluation of human samples derived from clinical trials. This will be a highly collaborative enterprise with the groups of Kammüller and Terranova from NIBR-PCS and with multiple Novartis departments as well as external academic and biotech partners. Our translational sciences approach will provide new insights for the development of transformative medicines for patients in need.